At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 359 enrolled
Drug / intervention
FF/VI +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, 12 Week, Randomized, Double-blind, 4 Arm Parallel Group Bridging Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI Once-daily Via a Dry Powder Inhaler With Dual Combination of FF/VI, Administered in Chinese Participants With Inadequately Controlled Asthma
In Brief
A Phase 3 clinical trial evaluating FF/VI, FF/UMEC/VI, and 1 other intervention for Asthma. Completed, enrolled 359 participants across 61 sites.
Detailed Summary
The study aims to evaluate the efficacy, safety and tolerability of FF/UMEC/VI compared with FF/VI via ELLIPTA® inhaler in Chinese participants with inadequately controlled asthma. ELLIPTA is a registered trademark of GlaxoSmithKline group of companies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedJun 2021
Enrollment StartJul 2021
Primary CompletionAug 2024
TodayJul 2026
First PostedJun 24, 2021
Enrollment StartJul 29, 2021
Primary CompletionAug 5, 2024
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 5.0 years ago
Interventions
FF/VIdrug
FF/VI will be administered.
FF/UMEC/VIdrug
FF/UMEC/VI will be administered.
ELLIPTAdevice
FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler.